Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Praxis Precision Medicines ( (PRAX) ) has shared an update.
On April 14, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration accepted for review its New Drug Application for ulixacaltamide HCl to treat essential tremor in adults. The FDA set a Prescription Drug User Fee Act target action date of January 29, 2027 and indicated it does not plan to convene an advisory committee, signaling a potentially streamlined regulatory path for this late-stage asset in a high-need neurological indication.
The most recent analyst rating on (PRAX) stock is a Buy with a $545.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.
Spark’s Take on PRAX Stock
According to Spark, TipRanks’ AI Analyst, PRAX is a Neutral.
The score is supported primarily by positive earnings-call fundamentals (meaningful NDA/regulatory progress and a strong cash runway into 2028) and a low-leverage balance sheet. These are tempered by very weak current financial performance (zero revenue in 2025, widening losses, and accelerating cash burn), with mixed technical signals and limited support from valuation metrics due to losses and no stated dividend yield.
To see Spark’s full report on PRAX stock, click here.
More about Praxis Precision Medicines
Praxis Precision Medicines, Inc. is a biopharmaceutical company focused on developing novel therapies for neurological disorders. Its pipeline includes drug candidates targeting central nervous system conditions with significant unmet medical need, aiming to serve adult patient populations with limited existing treatment options.
Average Trading Volume: 452,103
Technical Sentiment Signal: Buy
Current Market Cap: $8.8B
Learn more about PRAX stock on TipRanks’ Stock Analysis page.